Topical cyclosporine in pediatric keratoplasty

Eye and Contact Lens

Volumn 29, Issue 2, 2003, Pages 103-107

  Cosar, C Banu ^a   Laibson, Peter R ^a   Cohen, Elisabeth J ^a,b   Rapuano, Christopher J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

Cyclosporine; Pediatric keratoplasty; Penetrating keratoplasty

Indexed keywords

ACETYLCYSTEINE; ANTIGLAUCOMA AGENT; ARTIFICIAL TEAR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; TEARS PLUS; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

AGE; ARTICLE; CATARACT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOTHERAPY; DESCEMET MEMBRANE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EYE; FEMALE; FOLLOW UP; GLAUCOMA; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH STATUS; HUMAN; INFANT; INTRAOCULAR PRESSURE; KAPLAN MEIER METHOD; KERATITIS; KERATOPATHY; LENS; LUNG TUBERCULOSIS; MALE; MEDICAL INFORMATION; NEWBORN; PENETRATING KERATOPLASTY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECIPIENT; RETINA DETACHMENT; RETINA TEAR; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX; STATISTICAL SIGNIFICANCE; STRABISMUS; SURVIVAL RATE; SUTURE REMOVAL; TREATMENT FAILURE; COMPARATIVE STUDY; CORNEA; DRUG COMBINATION; DRUG EFFECT; PRESCHOOL CHILD; SAFETY; TOPICAL DRUG ADMINISTRATION; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; CORNEA; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTRAOCULAR PRESSURE; KERATOPLASTY, PENETRATING; MALE; RETROSPECTIVE STUDIES; SAFETY; VISUAL ACUITY;

EID: 0037531367     PISSN: 15422321     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ICL.0000062460.03555.32     Document Type: Article

References (26)

1. Gloor P. Pediatric penetrating keratoplasty. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea vol 3. St. Louis, Mosby-Year Book, Inc. 1997 pp 1731-54.
2. Hoffmann F, Wiederholt M. Local treatment of corneal transplant in humans with cyclosporin A. Klin Mbl Augenheilk 1985;187:92-6.
3. Goichot-Bonnat L, De Beauregard C, Saragoussi JJ, et al. Use of topical cyclosporine A to prevent the corneal rejection. J Fr Ophthalmol 1987;10(3):207-11.
4. Goichot-Bonnat L, Chemla P, Pouliquen Y. Topical cyclosporine A to prevent the corneal rejection. J Fr Ophthalmol 1987;10(3):213-7.
5. Belin MW, Bouchard CS, Frantz S, et al. Topical cylosporine in high-risk corneal transplants. Ophthalmology 1996; 1144-50.
6. Gunduz K, Ozdemir O. Therapeutic use of topical cyclosporine. Ann Ophthalmol 1993;25:182-6.
7. Zhao JC, Jin XY. Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol 1994;119:189-94.
8. Geggel HS. Successful penetrating keratoplasty in a patient with severe atopic keratoconjunctivitis and elevated serum IgE level treated with long-term topical cyclosporin A. Cornea 1994;13(6):543-6.
9. Wehrly SR, Manning FJ, Proia AD, et al. Cytomegalovirus keratitis after penetrating keratoplasty. Cornea 1995;14(6):628-33.
10. Perry HD, Donnenfeld ED, Kanellopoulos AJ, et al. Topical cyclosporin A in the management of postkeratoplasty glaucoma. Cornea 1997;16(3):284-8.
11. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporin A into the cornea and anterior chamber. CLAO J 1998;24(3):159-65.
12. Inoue K, Amano S, Kimura C, et al. Long-term outcome of topical cyclosporine treatment following penetrating keratoplasty. Nippon Ganka Gakkai Zasshi 1999;103(4):306-10.
13. Turacli ME, Gunduz K, Aktan G, et al. Topical cyclosporine as a possible new antimetabolite in trabeculectomy. Ophthalmic Surg Lasers 1996;27:438-44.
14. Finger PT, Czechonska G, Demirci H, et al. Chemotherapy for retinoblastoma: a current topic. Drugs 1999;58(6):983-6.
15. Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol 1999;83(11):1225-9.
16. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea 1990;9(3):184-95.
17. Stulting RD, Sumers KD, Cavanagh HD, et al. Penetrating keratoplasty in children. Ophthalmology 1984;91:1222-30.
18. Dana MR, Moyes AL, Gomes JAP, et al. The indications for and outcome in pediatric keratoplasty. Ophthalmology 1995;102:1129-38.
19. Leibowitz HM. Ocular toxicity of corticosteroids. In: Leopold IH, Burns RP (eds): Symposium on Ocular Therapy vol 2. New York, John Wiley and Sons 1979 pp 108-9.
20. Nussenblatt RB, Palestine AG. Cyclosporine: Immunology, pharmacology, and therapeutic uses. Surv Ophthalmol 1986;31:159-69.
21. Parmar MKB, Machin D. Survival Analysis A Practical Approach. New York, John Wiley and Sons 1995 pp 30-1.
22. Hoffmann F, Wiederholt M. Topical cyclosporin A in the treatment of corneal graft rejection. Cornea 1986;5(3):129.
23. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. Ophthalmology 2000;107:967-74.
24. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107:631-9.
25. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993;12(5):413-9.
26. Hill JC. Systemic cyclosporine in high-risk keratoplasty: Short- versus long-term therapy. Ophthalmology 1994;101:128-33.